Home » Regions » Global News » Phase Forward Q3 Revenues Jump 24%, Earnings Down by Half

Phase Forward Q3 Revenues Jump 24%, Earnings Down by Half

Friday, October 30, 2009

Waltham, Mass-based Phase Forward, a provider of data management solutions for clinical trials and drug safety, reported third quarter revenues jumped 24% to $53.1 million, compared with the third quarter of 2008, but earnings were cut in half.

For the third quarter, income from operations was $2.4 million, compared with $4.4 million in the third quarter of 2008. Net income for the period was $1.8 million, or $0.04 per diluted share, compared with $0.08 per diluted share in 2008.

Within total revenues, electronic data capture license, application hosting and other related revenues were $38.5 million, representing 71% of third quarter total revenues and an increase of 18% from $32.7 million in the prior year period.

Bob Weiler, chairman and CEO, said, “The combination of solid revenue growth and expense management led to non-GAAP operating income and EPS that were above our guidance for the quarter.”

Total cash, cash equivalents and investments were $147.2 million at the end of the third quarter, which was down from $168.7 million at the end of the prior quarter because Phase Forward spent approximately $21 million used in the previously announced acquisitions of Maaguzi and Covance’s IRT business unit.

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!